Department of Pharmaceutics, College of Pharmaceutical Sciences, Soochow University, Jiangsu Suzhou 215123, China.
Department of Pharmaceutics, College of Pharmaceutical Sciences, Soochow University, Jiangsu Suzhou 215123, China; Department of Pharmacy, Changzhou the Second People's Hospital Affiliated to Nanjing Medical University, Jiangsu Changzhou 213000, China.
Acta Biomater. 2022 Nov;153:481-493. doi: 10.1016/j.actbio.2022.09.046. Epub 2022 Sep 24.
Clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) system adapted from bacteria is a programmable nuclease-based genome editing tool. The long-lasting effect of gene silencing or correction is beneficial in cancer treatment. Considering the need to broaden the practical application of this technology, highly efficient non-viral vectors are urgently required. We prepared a multifunctional non-viral vector that could actively target tumor cells and deliver CRISPR/Cas9 plasmids into nuclei of cancer cells. Protamine sulfate (PS) which contains nuclear localization sequence was utilized to condense plasmid DNA and facilitate nuclei-targeted delivery. Liposome-coated protein/DNA complex avoided the degradation of nuclease in blood circulation. The obtained PS@Lip/pCas9 was further modified with distearoyl phosphoethanolamine-polyethylene glycol-hyaluronic acid (HA) to endow the vector ability to actively target tumor cell. Results suggested that PS@HA-Lip could deliver CRISPR/Cas9 plasmids into nuclei of tumor cells and induce genome editing effect. With the disruption of MTH1 (mutT homolog1) gene, the growth of non-small cell lung cancer was inhibited. Moreover, cell apoptosis in tumor tissue was promoted, and liver metastasis of non-small cell lung cancer (NSCLC) was reduced. Our study has provided a therapeutic strategy targeting MTH1 gene for NSCLC therapy. STATEMENT OF SIGNIFICANCE: CRISPR/Cas9 as a powerful tool for genome editing has drawn much attention. The long-lasting effect possesses unique advantage in cancer treatment. Non-viral vectors have high loading capacity, high safety and low immunogenicity, playing an important role in CRISPR/Cas9 delivery. In our study, a multifunctional non-viral vector for the efficient delivery of CRISPR/Cas9 plasmid was constructed. With the active targeting ligand and nuclei-targeting component, the cargo was efficiently delivered into cell nuclei and exerted genome editing effect. By using this vector, we successfully inhibited the growth and induced the apoptosis of non-small cell lung cancer by disrupting MTH1 expression with good safety. Our work provided an efficient non-vial vector for CRISPR/Cas9 delivery and explored the possibility for cancer treatment.
源自细菌的成簇规律间隔短回文重复 (CRISPR)/CRISPR 相关蛋白 9 (Cas9) 系统是一种可编程的基于核酸酶的基因组编辑工具。基因沉默或纠正的持久效果有益于癌症治疗。考虑到需要扩大这项技术的实际应用,迫切需要高效的非病毒载体。我们制备了一种多功能非病毒载体,能够主动靶向肿瘤细胞,并将 CRISPR/Cas9 质粒递送到癌细胞的核内。含有核定位序列的硫酸鱼精蛋白 (PS) 用于浓缩质粒 DNA 并促进核靶向递药。包被有脂质体的蛋白/DNA 复合物可避免核酶在血液循环中的降解。所得 PS@Lip/pCas9 进一步用二硬脂酰基磷脂酰乙醇胺-聚乙二醇-透明质酸 (HA) 进行修饰,赋予载体主动靶向肿瘤细胞的能力。结果表明,PS@HA-Lip 能够将 CRISPR/Cas9 质粒递送到肿瘤细胞核内,并诱导基因组编辑效应。通过破坏 MTH1(mutT 同源物 1)基因,抑制非小细胞肺癌的生长。此外,还促进了肿瘤组织中的细胞凋亡,并减少了非小细胞肺癌(NSCLC)的肝转移。我们的研究为 NSCLC 治疗提供了针对 MTH1 基因的治疗策略。
CRISPR/Cas9 作为一种强大的基因组编辑工具引起了广泛关注。其持久效果在癌症治疗中具有独特的优势。非病毒载体具有高载药量、高安全性和低免疫原性的特点,在 CRISPR/Cas9 递送中发挥着重要作用。在本研究中,构建了一种用于高效递送 CRISPR/Cas9 质粒的多功能非病毒载体。通过使用主动靶向配体和核靶向组件,有效将 cargo 递送到细胞核内并发挥基因组编辑作用。通过使用该载体,我们成功地通过破坏 MTH1 表达抑制了非小细胞肺癌的生长并诱导了其凋亡,且具有良好的安全性。我们的工作为 CRISPR/Cas9 递送提供了一种高效的非病毒载体,并探索了其在癌症治疗中的可能性。